earnings
confidence high
sentiment negative
materiality 0.65
Arrowhead Q1 net loss widens to $0.60/share; GSK licenses NASH candidate
ARROWHEAD PHARMACEUTICALS, INC.
2022-Q1 EPS reported
-$0.60
revenue$27,439,000
- Net loss of $62.9M ($0.60 diluted EPS) vs $20.7M ($0.20) in prior year quarter.
- Revenue rose to $27.4M from $21.3M, primarily from license and collaboration revenue.
- R&D expense nearly doubled to $65.8M; G&A expense tripled to $25.0M.
- Initiated PALISADE Phase 3 study for ARO-APOC3 in familial chylomicronemia syndrome.
- Entered exclusive license with GSK for ARO-HSD (NASH); advanced two pulmonary candidates.